On October 16, 2025 EORTC reported it will be prominently featured at the EANO 2025 conference, held in Prague from 16 to 19 October. Our team will present seven scientific abstracts, including two oral presentations and five posters, highlighting ongoing research in neuro-oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition, EORTC projects will be featured in a joint session with the Brain Tumour Group (BTG), where six participants will present on clinical trial planning and current case studies, highlighting the collaborative efforts within EORTC to advance cancer research.
Further details can be found in the table below.
EORTC ABSTRACTS
AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE
Ogechukwu Edeh-Asogwa, Netherlands Friday, 17 October 10:35 – 10:45
Type: Oral session
Room: Forum Hall
FINAL CLINICAL AND MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION
Martin Van Den Bent, Netherlands Saturday, 18 October 11:25 – 11:35
Type: Oral session
Room: Forum Hall
EANO, EORTC, EPTN and ESNR consensus-based definition for post-radiotherapy MRI abnormalities in the brain: preliminary findings from an interdisciplinary Delphi study
Maarten Lambrecht, Belgium Friday, 17 October 17:00 – 18:30
Type: Poster session
Room: Forum Hall Foyer 3
VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Marjolein Geurts, Netherlands Friday, 17 October 18:00 – 19:30
Type: Poster session
Room: Forum Hall Foyer 3
MGMT METHYLATION DURING THE PROGRESSION OF GLIOBLASTOMA
Bo Deng, Netherlands Saturday, 18 October 17:00 – 18:30
Type: Poster session
Room: Forum Hall Foyer 3
THE USE OF EORTC QLQ-C30 SUMMARY SCORE IN CANCER CLINICAL TRIALS AND ITS PERFORMANCE AS COMPARED WITH THE GLOBAL HEALTH / QUALITY OF LIFE SCALE: A COMPARATIVE ANALYSIS OF EFFECT SIZES
Josien Scheepens, Netherlands Saturday, 18 October 17:00-18:30
Type: Poster session
Room: Forum Hall Foyer 3
ASSOCIATION BETWEEN TEMOZOLOMIDE-RELATED HEMATOLOGICAL TOXICITY AND HRQOL SCORES IN GLIOBLASTOMA: A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS
Clemens Seidel, Deutschland Sunday, 19 October 2025 12:00-12:45
Type: Poster session
Room: Forum Hall Foyer 3
SESSIONS
WHAT CAN A SUPPORTING AGENCY SUCH AS EORTC DO FOR YOU?
Michael Weller, Switzerland JOINT SESSION
Saturday, 18 October 08:00 – 08:14
South Hall 2
CLINICAL TRIAL MANAGEMENT: STEERING COMMITTEE, THE MEDICAL MONITOR AND THE DATA MONITORING COMMITTEE
Patrick Roth, Switzerland JOINT SESSION
Saturday, 18 October 08:14 – 08:28
South Hall 2
EORTC-2227 (LEGATO): LOMUSTINE WITH AND WITHOUT REIRRADIATION FOR FIRST PROGRESSION OF GLIOBLASTOMA: A RANDOMIZED PHASE III STUDY
Tomas Kazda, Czech Republic JOINT SESSION
Saturday, 18 October 08:28 – 08:36
South Hall 2
EORTC-2334 (LUMEN-1): 177LU-DOTATATE FOR RECURRENT MENINGIOMA: A RANDOMIZED PHASE II STUDY
Emeline Tabouret, France JOINT SESSION
Saturday, 18 October 08:36 – 08:44
South Hall 2
EORTC 2427 (VIGOR): VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: A PLACEBO-CONTROLLED RANDOMIZED PHASE III STUDY
Marta Padovan, Italy JOINT SESSION
Saturday, 18 October 08:44 – 08:52
South Hall 2
EORTC-2013 (GLIO-RARE): OBSERVATIONAL STUDY FOR ASSESSING TREATMENT AND OUTCOME OF PATIENTS WITH PRIMARY BRAIN TUMOURS DIAGNOSED ACCORDING TO CIMPACT-NOW RECOMMENDATIONS AND THE 2021 WHO CLASSIFICATION
Maximilian Mair, Austria JOINT SESSION
Saturday, 18 October 08:52 – 09:00
South Hall 2
(Press release, EORTC, OCT 16, 2025, View Source [SID1234656701])